EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States)
Key facts
- Who runs it
- Polares Medical SA
- Where
- Atlanta, Cincinnati, and The Bronx, United StatesSee the 3 sites
- Trial code
- Status
- Recruiting
- People taking part
- 15 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Dec 2032
- Type of study
- Interventional
- Treatments tested
- MR-ace Implant and Delivery System
- Record updated
- 1 September 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 42 criteriaShow less
Who can take part
- Patient has symptomatic moderate-to-severe to severe functional mitral regurgitation despite stable doses of maximally tolerated guideline directed medical therapy (GDMT) per the Local Heart Team; Note: In the 30 days prior to performing screening assessments, no new GDMT medications should be introduced and current doses should be stable (i.e. no decrease of > 50% or increase of > 100%) excluding diuretics. Any changes beyond this range would not be considered stable GDMT
- Functional MR graded 3+ or higher (using a scale of 0 to 4+) by transthoracic echocardiography (TTE) within 60 days prior to study procedure as evaluated by the sponsor's Echo Core Lab
- New York Heart Association (NYHA) Functional Class II, III or ambulatory IV heart failure
- Patient must present with an STS Score less than 10% and deemed by the Local Heart Team to be at high risk but operable for mitral valve surgery
- The Local Heart Team deems the patient unsuitable for commercially approved transcatheter mitral valve therapies
- 21 years of age or older
- Native mitral valve geometry and size is compatible with the Polares MRace system
- Anatomy is suitable for transfemoral transseptal access with the Polares MRace system
- Patient is willing to participate in study and provides signed IRB/EC-approved informed consent
- Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits
- Patient is approved by an independent Patient Eligibility Committee
Who cannot take part
- Previous mitral valve surgery or transcatheter mitral valve procedure
- Prior orthotopic heart transplantation
- Untreated Class I indication for pacing (CRT). Implant or revision of any pacing device < 30 days prior to intervention
- Any untreated clinically significant coronary artery disease requiring revascularization. Coronary, carotid, or endovascular artery disease treated percutaneously < 30 days prior to study procedure. Cardiac surgery < 90 days prior to study procedure
- Myocardial infarction requiring intervention < 30 days prior to study procedure
- Active peptic ulcer or upper gastrointestinal bleeding < 90 days prior to study procedure
- Stroke < 180 days prior to study procedure
- Severe COPD requiring oral steroid therapy or oxygen therapy
- Concurrent medical condition with a life expectancy of less than 2 years
- Severe Right Ventricle (RV) dysfunction as per assessment by Local Heart Team or Eligibility Committee
- Severe aortic stenosis or insufficiency
- Barlow's disease
- Active infection or endocarditis or infection requiring antibiotic therapy within 2 weeks of scheduled procedure
- Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus. History of deep vein thrombosis (DVT) or pulmonary embolism within 6 months of the index procedure
- Cardiogenic shock at time of enrolment. Hemodynamic instability requiring inotropic support or mechanical heart assistance
- Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated; Note. Patient must be able to tolerate at least one antiplatelet medication AND one anticoagulant medication
- Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial/procedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments
- Patient is in need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
- Patient is considered to be part of a vulnerable population, is under guardianship, or subject to any other medical, social or psychological conditions that preclude appropriate consent and follow-up
- Echocardiographic parameters (any of the following, assessed by the Echo Core Lab); Left ventricular ejection fraction (LVEF) < 30%; Pulmonary artery systolic pressure (PASP) > 70mmHg or > 2/3 SBP (Systolic Blood Pressure); Left Ventricle End Diastolic Volume (LV EDV) > 200 mL; Left Ventricle End Systolic Volume (LV ESV) > 140 mL; Left Ventricle End Diastolic Diameter (LV EDD) > 70 mm; Left Ventricle End Systolic Diameter (LV ESD) > 55 mm
- Severe renal insufficiency (creatinine > 3.0 mg/dL) or patient requiring dialysis
- History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3,000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL)
- Severe tricuspid regurgitation
- Severe mitral annulus calcification
- Diseased mitral anterior and/or posterior leaflet, such as flail, / prolapse, or/ heavy moderate to severe calcification
- Presence of an implanted vena cava filter or any other device (e.g. ASD closure device) that may interfere with femoral vein access or delivery system access to the mitral valve
- Contraindication for transesophageal echocardiography (TEE) or MDCT scan
- Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis)
- Pregnancy or breastfeeding at time of enrolment with a positive pregnancy test within 14 days of study procedure
- Company employees or their immediate family members
- Patient is participating in another clinical study for which follow-up is currently ongoing
Where in United States
- Emory MidtownAtlanta, United StatesContact: Elizabeth CharlesTaking people
- The Lindner Research Center at the Christ HospitalCincinnati, United StatesContact: Katy FischesserNot yet recruiting
- Montefiore Medical CenterThe Bronx, United StatesContact: Tammy GuzmanNot yet recruiting
About the trial
What the trial wants to find out
The goal of this early feasibility clinical trial is to learn if the device MR-ace Implant and Delivery System works in patients with moderate or severe mitral valve regurgitation. It will also learn about the safety of the device MR-ace Implant and Delivery System. The main questions it aims to answer are:
Read full original descriptionShow less
Does implanting the MR-ace device reduce the symptoms of mitral regurgitation? Does the device reduce the the leak through your mitral valve?
Participants will:
Be implanted with the device Visit the clinic for checkups and tests at 30 days, 6 months, 12 months, and 2, 3, 4 and 5 years following your procedure Complete a quality of life survey
The group in the trial
- TreatmentTreatment being tested
treatment with the study device
Treatment: MR-ace Implant and Delivery System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Feasibility Experience of Posterior Leaflet Replacement to Reduce Mitral Regurgitation Using the MRace Implant (United States)
- Record updated
- 1 September 2026